Save up -80% on Canakinumab

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
RX PCN: HT
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Canakinumab

$

* price without discount in nearest pharmacy. Price may vary.

Claim your free Canakinumab discount card

We offer free Canakinumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Canakinumab every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Canakinumab volume of distribution

* 6.01 L[typical CAPS patient weighing 70 kg]

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1 monoclonal antibody that belongs to the IgG1/ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.

Canakinumab mechanism of action

In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1 ) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1 , and mutations in cryopyrin’s gene, NLRP-3, up-regulate IL-1 activation. Canakinumab is a human monoclonal anti-human IL-1 antibody of the IgG1/ isotype. Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1 or IL-1 receptor antagonist (IL-1ra).

Dosage forms of Canakinumab

FormRouteStrength
Injection, powder, lyophilized, for solutionsubcutaneous150 mg/mL
Powder and solvent for solution for injectionSubcutaneous use150 mg
Powder for solutionsubcutaneous150 mg
Prescription Generics

false

International Brands

Ilaris

Synonyms

ACZ-885 ACZ885

Manufacturers

Novartis Pharmaceuticals Canada Inc

CAS number

914613-48-2

UNII

37CQ2C7X93

State

liquid

Affected organisms

Humans and other mammals

Indication of Canakinumab

Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).

Toxicity of Canakinumab

The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.

RX24 Drugs Disclaimer: before buying a Canakinumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Canakinumab now!